EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence

Jie Yang, Xingyu Xiong, Weitao Zheng, Xinyang Liao, Hang Xu, Lu Yang, Qiang Wei iD

Current Oncology · 04.12.2023 · 30 (12) · 10311-10324

DOI: 10.3390/curroncol30120751 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Current Oncology, online erschienen am 04.12.2023. Verfasst von Jie Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and Technology Innovation Talent Project of Sichuan, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical and clinical studies have suggested potential synergies of combining poly (ADP-ribose) polymerase (PARP) inhibitors and novel hormonal therapies (NHT) for patients with metastatic castration-resistant prostate cancer (mCRPC). We systematically searched PubMed, ClinicalTrials.gov and ASCO-GU annual meeting abstracts up to March 2023 to identify potential phase III trials reporting the use of combining PARP inhibitors with NHT in the first-line setting for mCRPC. A total of four phase III trials met the criteria for subsequent review. Emerging data suggested that the radiographic progression-free survival (rPFS) was significantly longer in the PARP inhibitor combined with NHT group versus the placebo plus NHT group for the first-line setting of biomarker-unselected mCRPC patients, especially for patients with homologous recombination repair (HRR) mutation (HRR m), and with the greatest benefit for BRCA1/2 mutation (BRCA1/2 m) populations. Final overall survival (OS) data of the PROpel trial indicated a significant improvement in median OS for mCRPC patients with HRR m and BRCA1/2 m receiving olaparib + abiraterone. Prior taxane-based chemotherapy might not influence the efficacy of the combination. Compared with the current standard-of-care therapies, combining NHT with PARP inhibitors could achieve a significant survival benefit in the first-line setting for mCRPC patients with HRR and BRCA1/2 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntineoplastic AgentsMaleHumansPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinRiboseBRCA2 Protein

Stichwörter der Autor:innen

first-line therapyhomologous recombination repairmCRPCpoly (ADP-ribose) polymerase inhibitor

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanBRCA1 ProteinRiboseBRCA2 protein, humanBRCA2 ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China.

ORCID-Profile: Qiang Wei

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Science and Technology Innovation Talent Project of Sichuan, China
  • Clinical Research Incubation Project of West China Hospital of Sichuan University

Zitieren

APA

Yang, J., Xiong, X., Zheng, W., Liao, X., Xu, H., Yang, L., & Wei, Q. (2023). Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence. Current Oncology, 30(12), 10311-10324. https://doi.org/10.3390/curroncol30120751

Vancouver

Yang J, Xiong X, Zheng W, Liao X, Xu H, Yang L, et al. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence. Current Oncology. 2023;30(12):10311-10324. doi:10.3390/curroncol30120751

BibTeX
@article{Yang2023,
  author = {Yang, Jie and Xiong, Xingyu and Zheng, Weitao and Liao, Xinyang and Xu, Hang and Yang, Lu and Wei, Qiang},
  title = {Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {12},
  pages = {10311--10324},
  doi = {10.3390/curroncol30120751}
}
Kostenlos starten →